Are executive health check-ups worth it? The trials tested a simpler check

Neither of the two reviews behind this page describes a trial of the private multi-scan package sold as an executive health check-up, so the closest tested thing is the general health check: screening for more than one disease or risk factor, in more than one organ system, in adults who have no symptoms [4]. Across 11 randomised trials and 233,298 adults, 21,535 people died, and the share who died was the same with checks as without them [4].

Every specific cause the reviewers could pool came out level too [4]:

• cancer deaths, across 8 trials and 139,290 adults, with 3,663 deaths
• deaths from heart and circulatory disease, across 9 trials and 170,227 adults, with 6,237 deaths
• heart disease of any severity, fatal or not, across 4 trials and 164,881 people, with 10,325 events
• stroke, fatal or not, across 3 trials and 107,421 people, with 4,543 events

The reviewers graded the findings for deaths overall and for heart disease at their highest grade of reliability. The two circulatory findings were graded one step lower, because the trials disagreed with each other [4].

A 2021 review in JAMA cast a wider net and landed in the same place: 19 randomised trials, from 906 to 59,616 people each, followed for anywhere between 1 and 30 years, plus 13 studies comparing people who did and did not attend [5]. The South-East London Screening Study covered 7,229 adults aged 40 to 64, and among those invited to two checks over two years the review records no survival benefit eight years on: 6% had died, against 5% of those not invited [5].

What checks did change was what doctors knew and did next. They were linked to more chronic illness being picked up, depression and high blood pressure among it, modest gains in blood pressure and cholesterol control, and more people going on to have cancer screening [5]. In a matched comparison of 8,917 people, 69% of those who attended a Medicare wellness visit later had bowel cancer screening, against 60% of those who did not [5].

Prescribing moved as well. In the Danish Check-In study, 1,104 adults were randomly assigned to a single check or to usual care, and over the following year 5% of the check group started a new antidepressant, against 2% of the others [5]. Behaviour barely shifted: in the OXCHECK trial of 4,121 adults, 68% of those offered annual checks exercised less than once a month, against 71% of those not offered them, a gap of about 3 people in 100 [5].

A check-up treats nothing. It moves information earlier in time, and that only pays off when three things line up: the problem found behaves better when caught early, a treatment exists that changes its course, and the person actually gets that treatment.

In adults with no symptoms, most of what a broad screen turns up is risk factors rather than illness, a blood pressure reading or a cholesterol number, and those are the same things ordinary primary care measures when someone comes in for anything else [5]. Finding them sooner shortens the timeline without changing where most people end up.

Looking harder also creates work, and the work carries its own risk. The Cochrane reviewers put it plainly: screening leads to more diagnostic tests and more treatment, which can harm as well as help [4]. Individual studies in the JAMA review logged possible harms including a raised stroke risk, and higher mortality that the authors traced to more people completing advance directives, the documents stating which treatments a person would refuse [5].

The trials tested something cheaper and plainer than what people are shopping for. Cochrane defined a health check as screening for more than one disease or risk factor, in more than one organ system, in adults not selected for being ill [4]. That is a blood panel and a handful of measurements, not whole-body imaging, glucose sensors or advanced biomarker panels, and neither review describes a trial of a package like that [4][5].

The evidence does not apply to:

• older people as a group, because Cochrane left out trials run in geriatric populations [4]
• anyone already diagnosed with what is being screened for, since these trials enrolled adults unselected for disease [4]
• anyone with symptoms, who is not being screened at all but investigated

Certainty was uneven. Deaths overall and heart disease were graded most reliable, while circulatory deaths and stroke were graded a step lower because the trials pointed in different directions [4].

And 13 of the studies in the JAMA review compared people who attended a check with people who did not, rather than randomising them [5]. Someone who books a check-up and turns up for it is different from someone who does not, in ways no statistical adjustment fully strips out.

Longevity clinics sell this as the executive physical or the comprehensive health assessment, and the directory lists it as a service category of its own. A first visit is typically built around a fasting blood draw and a broad laboratory panel, blood pressure and body composition measurements, a fitness or cardiac test, sometimes imaging, and then a consultation that goes through the results and sets the follow-up.

The trials above give someone booking one a narrow but useful thing to hold on to. The parts that overlap with a general health check have been tested on hundreds of thousands of adults and did not move death rates [4], while the scans and panels layered on top have not been tested that way at all. The question worth putting to a clinic is which of its findings would change what anyone does next, because a result that leads nowhere is one you pay for twice, once for the test and again for the follow-up it triggers.